TAS2R3 Antibody

What is TAS2R3 and what are its primary functions?

TAS2R3 (Taste Receptor Type 2 Member 3) is a G-protein coupled receptor that functions primarily as a bitter taste receptor. While initially characterized for its role in taste perception, TAS2R3 has been identified in multiple extraoral tissues, suggesting broader physiological functions beyond gustatory sensation . Research has demonstrated that TAS2R3, like other T2R family members, may play roles in endocrine regulation, specifically in relation to thyroid function as evidenced by its association with thyroid hormone levels .

What are the common applications for TAS2R3 antibodies in research?

TAS2R3 antibodies are primarily used for protein detection via Western Blotting (WB), enzyme-linked immunosorbent assay (ELISA), and immunofluorescence (IF) techniques . These applications allow researchers to:

• Detect and quantify TAS2R3 expression in various tissue types

• Investigate receptor localization at cellular and subcellular levels

• Assess changes in receptor expression under different experimental conditions

• Validate genetic findings with protein-level confirmation

The diversity of antibody conjugates available (including unconjugated, APC, biotin, FITC, and PE) provides flexibility in experimental design for multicolor flow cytometry and multiplexed immunoassays .

What are the key specifications to consider when selecting a TAS2R3 antibody?

When selecting a TAS2R3 antibody for research, several critical specifications should be evaluated:

• Binding Specificity: Target epitope location (e.g., AA 287-313, C-Term) which determines what region of the receptor the antibody recognizes

• Species Reactivity: Ensure compatibility with your experimental model (most commercial antibodies target human TAS2R3)

• Host Species: Typically rabbit for polyclonal antibodies, which influences secondary antibody selection and potential cross-reactivity

• Clonality: Polyclonal antibodies offer broader epitope recognition while monoclonal provides higher specificity

• Conjugation: Available options include unconjugated, APC, biotin, FITC, and PE depending on detection method requirements

• Validation Data: Evidence of antibody performance in specific applications (Western blot, IF, ELISA)

The selection should be guided by your specific experimental requirements and the technical parameters of your detection system.

How can TAS2R3 antibodies be used to investigate genetic variations in taste perception?

TAS2R3 antibodies can be employed in conjunction with genetic analysis to correlate genotype with protein expression patterns. Research has identified specific haplotypes in TAS2R3/4 genes that correlate with physiological outcomes, particularly the CC haplotype (rs2270009 and rs2234001) which is associated with reduced risk for papillary thyroid carcinoma (PTC) .

Methodological approach:

• Genotype subjects for known TAS2R3 variants

• Use TAS2R3 antibodies to quantify receptor expression in relevant tissues

• Perform co-immunoprecipitation to identify interaction partners that may differ between genetic variants

• Correlate antibody-detected protein levels with physiological parameters (e.g., TT3 hormone levels)

This integrated approach allows researchers to establish functional consequences of genetic polymorphisms at the protein level. Data has shown that carriers of the CC haplotype exhibit significantly lower levels of triiodothyronine (TT3) compared to non-carriers (1.04 ± 0.03 vs. 1.16 ± 0.01, p = 0.005) .

What methodological considerations are critical when using TAS2R3 antibodies for extraoral tissue analysis?

Investigating TAS2R3 in extraoral tissues presents unique challenges requiring methodological adaptations:

• Tissue-specific expression levels: Expression of TAS2R3 in extraoral tissues is generally lower than in taste buds, necessitating optimized protein extraction protocols and higher antibody concentrations

• Cross-reactivity concerns: Validate antibody specificity using appropriate negative controls (knockout tissues, peptide blocking)

• Signal enhancement strategies: Consider tyramide signal amplification for immunohistochemistry/immunofluorescence in tissues with low expression

• Subcellular localization: Membrane fractionation may be necessary to concentrate the receptor for detection

Research has confirmed TAS2R3 expression in white adipose tissue and adipocyte cell lines, suggesting roles beyond taste perception . When examining such tissues, antibody dilution series and extended exposure times for Western blots are recommended to detect potentially low abundance signals.

How do TAS2R3 antibodies contribute to understanding receptor function in metabolic processes?

TAS2R3 antibodies have proven valuable in elucidating the role of bitter taste receptors in metabolic regulation, particularly:

• Differentiation processes: Antibodies can track TAS2R3 expression changes during adipocyte differentiation, where Tas2r family genes show increased expression upon induction of differentiation

• Signaling pathway analysis: Immunoprecipitation with TAS2R3 antibodies followed by mass spectrometry can identify novel interaction partners

• Functional inhibition: Blocking antibodies can disrupt receptor function to assess physiological consequences

• Response to stimuli: Antibodies can quantify receptor upregulation in response to environmental factors such as serum deprivation or bitter compound exposure

Research indicates that overexpression of related Tas2r receptors (Tas2r108, Tas2r126) reduces adipocyte differentiation, suggesting that TAS2R3 may similarly influence adipogenesis through modulation of key transcription factors like PPARγ and C/EBPα .

What are the optimal protocols for Western blotting with TAS2R3 antibodies?

Western blotting with TAS2R3 antibodies requires specific optimization due to the receptor's membrane-bound nature and typically low expression levels:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors for total protein extraction

  • Consider membrane fractionation to concentrate the receptor

  • Avoid excessive heating (>70°C) which can cause receptor aggregation

• Gel electrophoresis:

  • Load adequate protein (50-100 μg for most tissues)

  • Use gradient gels (4-12%) to improve resolution

• Transfer and blocking:

  • PVDF membranes are preferable for hydrophobic membrane proteins

  • Block with 5% BSA rather than milk to reduce background

  • Include 0.1% Tween-20 in wash buffers

• Antibody incubation:

  • Primary antibody dilution: 1:500-1:1000 (optimize for each antibody)

  • Overnight incubation at 4°C for maximum sensitivity

  • Extended washing steps (5 x 5 minutes) to reduce background

• Detection:

  • Enhanced chemiluminescence with extended exposure times (up to 10 minutes)

  • Consider signal enhancement systems for tissues with low expression

This protocol has been validated for TAS2R3 antibodies targeting the C-terminal region (AA 287-313) .

How can researchers validate the specificity of TAS2R3 antibodies?

Validating antibody specificity is critical for reliable research outcomes. For TAS2R3 antibodies, implement these validation strategies:

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide (AA 287-313)

  • Run parallel Western blots with untreated and peptide-blocked antibody

  • Signal elimination confirms specificity for the target epitope

• Genetic controls:

  • Test antibody in CRISPR/Cas9 TAS2R3 knockout cells

  • Use siRNA knockdown to confirm signal reduction correlates with reduced expression

• Recombinant protein controls:

  • Test antibody against purified recombinant TAS2R3 protein

  • Include related TAS2R family members to assess cross-reactivity

• Multiple antibody validation:

  • Compare results using antibodies targeting different epitopes of TAS2R3

  • Consistent detection patterns increase confidence in specificity

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm pulled-down protein is indeed TAS2R3

These validation steps should be documented and reported in publications to ensure reproducibility and reliability of findings.

What are common pitfalls when using TAS2R3 antibodies and how can they be avoided?

Several common challenges arise when working with TAS2R3 antibodies:

• Non-specific binding:

  • Issue: Multiple bands on Western blots

  • Solution: Increase blocking time/concentration; optimize antibody dilution; try alternative blocking agents (BSA vs. milk)

• Weak or no signal:

  • Issue: Inadequate detection despite proper technique

  • Solution: Increase protein loading; extend exposure time; try membrane enrichment techniques; verify target expression in your sample type

• Inconsistent results between experiments:

  • Issue: Variable detection between replicates

  • Solution: Standardize protein extraction protocols; use fresh samples; aliquot antibodies to avoid freeze-thaw cycles

• Discrepancies between mRNA and protein detection:

  • Issue: mRNA detected but protein undetectable

  • Solution: Consider post-transcriptional regulation; try different antibodies targeting alternative epitopes; use more sensitive detection methods

• Cross-reactivity with related receptors:

  • Issue: Inability to distinguish between TAS2R family members

  • Solution: Perform parallel experiments with specific genetic knockdowns; use highly specific monoclonal antibodies when available

Careful optimization and validation for each experimental system are essential for generating reliable data with TAS2R3 antibodies.

How can TAS2R3 antibodies contribute to understanding the relationship between taste receptors and disease pathophysiology?

TAS2R3 antibodies enable investigation of receptor expression in various pathological states, providing insights into disease mechanisms:

• Thyroid disorders:
  Research has established links between TAS2R3/4 genetic variants and papillary thyroid carcinoma (PTC) risk. The data below demonstrates this association:

  Diplotype	Controls (%)	Cases (%)	Odds ratio (95% CI)	P-value
  TC/TC	229 (44.6)	121 (48.4)	1.00 (Reference)	-
  TC/CG	170 (33.1)	84 (33.6)	0.89 (0.64–1.27)	0.549
  CC/TC	63 (12.3)	14 (5.60)	0.43 (0.23–0.79)	0.007
  CG/CG	35 (6.82)	21 (8.40)	1.07 (0.59–1.94)	0.822
  CC/*	49 (15.4)	24 (9.60)	0.59 (0.36–0.97)	0.036

  TAS2R3 antibodies can determine if these genetic variations translate to altered protein expression or localization in thyroid tissue, potentially identifying biomarkers for disease susceptibility .

• Metabolic disorders:
  Evidence suggests taste receptors influence metabolic processes. Antibody-based studies can assess TAS2R3 expression in adipose tissue from diabetic vs. non-diabetic patients, potentially revealing receptor involvement in metabolic dysregulation .

• Respiratory conditions:
  Bitter taste receptors are expressed in airway epithelium. TAS2R3 antibodies can evaluate receptor distribution and abundance in respiratory samples from patients with chronic conditions, possibly identifying therapeutic targets.

Using TAS2R3 antibodies in these contexts requires careful correlation with clinical parameters and genetic data to establish meaningful associations.

What is the current evidence for using TAS2R3 detection as a biomarker in clinical research?

While TAS2R3 itself is not yet established as a clinical biomarker, research suggests potential applications:

• Thyroid function assessment:

  • TAS2R3/4 haplotypes correlate with triiodothyronine (TT3) levels

  • CC haplotype carriers show significantly lower TT3 levels (1.04 ± 0.03) compared to non-carriers (1.16 ± 0.01)

  • Antibody-based detection of TAS2R3 expression in conjunction with genetic analysis could provide complementary information to standard thyroid function tests

• Cancer research applications:

  • TAS2R3/4 CC haplotype is associated with reduced PTC risk (OR = 0.59)

  • Antibody-based detection of receptor expression in thyroid tumor samples could potentially distinguish risk groups

  • Correlation between receptor expression and tumor aggressiveness requires further investigation

• Metabolic profiling:

  • T2R family receptors influence adipocyte differentiation

  • Antibody detection of TAS2R3 in adipose biopsies might correlate with metabolic parameters

  • Longitudinal studies are needed to establish predictive value

Clinical implementation would require standardization of antibody-based detection methods and extensive validation in larger cohorts to establish sensitivity, specificity, and predictive value.

What are emerging techniques for studying TAS2R3 functionality beyond traditional antibody applications?

Several cutting-edge approaches complement traditional antibody-based methods for TAS2R3 research:

• CRISPR-Cas9 genome editing:

  • Generate TAS2R3 knockout or knock-in cell lines for functional studies

  • Create epitope-tagged endogenous TAS2R3 for improved detection

  • Introduce specific genetic variants to study polymorphism effects

• Single-cell transcriptomics and proteomics:

  • Characterize TAS2R3 expression at single-cell resolution

  • Identify cell populations with high receptor expression

  • Track expression changes during differentiation or disease progression

• Proximity labeling techniques:

  • Fuse TAS2R3 with BioID or APEX2 to identify proximal interacting proteins

  • Map the dynamic receptor interactome under various conditions

  • Identify signaling complexes specific to different tissues

• Advanced imaging approaches:

  • Super-resolution microscopy for precise receptor localization

  • Live-cell imaging with fluorescent ligands to track receptor dynamics

  • Correlative light and electron microscopy for ultrastructural context

• Organoid models:

  • Study TAS2R3 function in physiologically relevant 3D culture systems

  • Investigate tissue-specific roles in complex cellular environments

  • Test receptor-targeted interventions in personalized models

These techniques, used in conjunction with validated TAS2R3 antibodies, will provide deeper insights into receptor function across diverse physiological contexts.

How might TAS2R3 antibodies contribute to therapeutic development research?

TAS2R3 antibodies have potential applications in therapeutic research across several domains:

• Target validation:

  • Confirm TAS2R3 expression in disease-relevant tissues

  • Quantify receptor levels in patient samples to identify potential responders

  • Use blocking antibodies to assess phenotypic consequences of receptor inhibition

• Biomarker development:

  • Develop immunoassays for TAS2R3 detection in clinical samples

  • Correlate receptor expression with disease progression or treatment response

  • Identify patient subgroups based on receptor expression patterns

• Drug discovery applications:

  • Screen for compounds that modulate TAS2R3 expression or activity

  • Assess antibody-drug conjugates targeting TAS2R3-expressing cells

  • Evaluate off-target effects of bitter compounds on extraoral TAS2R3

• Therapeutic monitoring:

  • Track changes in receptor expression during treatment

  • Assess receptor internalization or degradation in response to therapeutics

  • Monitor receptor redistribution as a pharmacodynamic marker

The association between TAS2R3/4 genetic variants and PTC risk (OR = 0.43 for CC/TC diplotype) suggests potential applications in personalized medicine approaches for thyroid disorders, where targeted therapies might be developed based on receptor expression profiles.